AYLA Key Statistics, Chart & Performance
The current stock price of AYLA is 0.5036 USD. In the past month the price increased by 0.68%. In the past year, price decreased by -92.53%.
AYLA Latest News, Press Relases and Analysis
AYLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.92B | ||
| AMGN | AMGEN INC | 15.79 | 186.00B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.68 | 117.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 76.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 928.02 | 62.53B | ||
| INSM | INSMED INC | N/A | 44.10B | ||
| NTRA | NATERA INC | N/A | 32.88B | ||
| BIIB | BIOGEN INC | 10.8 | 26.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 20.71B | ||
| INCY | INCYTE CORP | 15.81 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About AYLA
Company Profile
Ayala Pharmaceuticals, Inc. operates as a clinical-stage oncology company. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-05-08. The firm's portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors (GSIs). AL101 and AL102 are designed to address the underlying key drivers of tumor growth. The firm is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC), for patients bearing Notch-activating mutations. The firm also developing AL102 for the treatment of other rare indications including T-ALL, an aggressive, rare form of T-cell specific leukemia. The firm is also conducting its ongoing Phase II ACCURACY trial for the treatment of R/M ACC in subjects with progressive disease and Notch-activating mutations.
Company Info
AYALA PHARMACEUTICALS INC
1313 N. Market Street, Suite 5100
Wilmington DELAWARE 7670104 US
CEO: Roni Mamluk
Employees: 35
Phone: 18574440553.0
AYALA PHARMACEUTICALS INC / AYLA FAQ
Can you describe the business of AYALA PHARMACEUTICALS INC?
Ayala Pharmaceuticals, Inc. operates as a clinical-stage oncology company. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-05-08. The firm's portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors (GSIs). AL101 and AL102 are designed to address the underlying key drivers of tumor growth. The firm is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC), for patients bearing Notch-activating mutations. The firm also developing AL102 for the treatment of other rare indications including T-ALL, an aggressive, rare form of T-cell specific leukemia. The firm is also conducting its ongoing Phase II ACCURACY trial for the treatment of R/M ACC in subjects with progressive disease and Notch-activating mutations.
Can you provide the latest stock price for AYALA PHARMACEUTICALS INC?
The current stock price of AYLA is 0.5036 USD. The price increased by 5.84% in the last trading session.
What is the dividend status of AYALA PHARMACEUTICALS INC?
AYLA does not pay a dividend.
What is the ChartMill technical and fundamental rating of AYLA stock?
AYLA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is AYALA PHARMACEUTICALS INC (AYLA) expected to grow?
The Revenue of AYALA PHARMACEUTICALS INC (AYLA) is expected to decline by -33.92% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for AYALA PHARMACEUTICALS INC?
AYALA PHARMACEUTICALS INC (AYLA) currently has 35 employees.
Can you provide the upcoming earnings date for AYALA PHARMACEUTICALS INC?
AYALA PHARMACEUTICALS INC (AYLA) will report earnings on 2023-03-27.
AYLA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AYLA. When comparing the yearly performance of all stocks, AYLA is a bad performer in the overall market: 96.41% of all stocks are doing better.
AYLA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AYLA. Both the profitability and financial health of AYLA have multiple concerns.
AYLA Financial Highlights
Over the last trailing twelve months AYLA reported a non-GAAP Earnings per Share(EPS) of -2.52. The EPS increased by 13.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AYLA Forecast & Estimates
9 analysts have analysed AYLA and the average price target is 12.24 USD. This implies a price increase of 2330.5% is expected in the next year compared to the current price of 0.5036.
For the next year, analysts expect an EPS growth of 3.59% and a revenue growth -33.92% for AYLA